EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Venetoclax-Based Regimens in Chronic Myelomonocytic Leukemia: A Systematic Review and Meta-Analysis

Mohammed Abdulgayoom, Mohammad S Afana, Leen Haj Saleh, Aadhila Abbas Manthiri, Noor A Aweer, Mohammad Bakheet, Abdulrahman F Al-Mashdali, Shehab F Mohamed

Acta Haematologica · 07.04.2026 · 1-16

DOI: 10.1159/000551885 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Acta Haematologica, online erschienen am 07.04.2026. Verfasst von Mohammed Abdulgayoom und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar, mmohammed35@hamad.qa. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chronic myelomonocytic leukemia (CMML) is a biologically heterogeneous myelodysplastic/myeloproliferative neoplasm with limited disease-modifying treatment options beyond hypomethylating agents (HMAs) and allogeneic hematopoietic stem cell transplantation. Venetoclax, a selective BCL-2 inhibitor, is increasingly used off-label in CMML, but its CMML-specific efficacy and safety remain incompletely defined.

Methods

We conducted a systematic review and meta-analysis in accordance with PRISMA 2020. Eligible studies included adult patients with CMML treated with venetoclax-based regimens and reporting extractable CMML-specific outcomes. PubMed, Embase, Cochrane CENTRAL, conference proceedings, and trial registries were searched through August 2025. Random-effects meta-analyses of proportions were performed for complete remission (CR), marrow complete remission (mCR), and overall response rate (ORR).

Results

Seventeen publications representing nine unique studies were included, comprising 145 venetoclax-treated CMML patients. Most regimens combined venetoclax with azacitidine, decitabine, or oral decitabine-cedazuridine, with heterogeneous dosing schedules and frequent CYP3A-guided dose modifications. Responses typically occurred early, within one to two treatment cycles, but durability was generally modest. The pooled CR rate was 19.1% (95% CI: 9.4–34.9; I2 = 55%), the pooled mCR rate was 36.4% (95% CI: 24.7–50.0; I2 = 21%), and the pooled ORR was 71.9% (95% CI: 56.5–83.4; I2 = 56%). Venetoclax-based therapy was associated with substantial myelosuppression, including frequent grade ≥3 neutropenia and thrombocytopenia, with clinically relevant infectious complications. Early mortality was low in studies reporting short-term outcomes.

Conclusion

Venetoclax-based regimens demonstrate measurable but limited activity in CMML, with high overall response rates but low CR rates and modest durability. Prospective CMML-specific trials are needed to define optimal dosing, clarify comparative effectiveness, and identify patients most likely to benefit.

Schlagwörter

Stichwörter der Autor:innen

BCL-2 inhibitionChronic myelomonocytic leukemiaHypomethylating agentsMeta-analysisSystematic reviewVenetoclax

Autor:innen und Institutionen

  • Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar, mmohammed35@hamad.qa.
  • Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.
  • College of Medicine, Qatar University, Doha, Qatar.
  • College of Pharmacy, Qatar University, Doha, Qatar.
  • College of Medicine, Omdurman Islamic University, Khartoum, Sudan.

Zitieren

APA

Abdulgayoom, M., Afana, M. S., Saleh, L. H., Manthiri, A. A., Aweer, N. A., Bakheet, M., Al-Mashdali, A. F., & Mohamed, S. F. (2026). Venetoclax-Based Regimens in Chronic Myelomonocytic Leukemia: A Systematic Review and Meta-Analysis. Acta Haematologica, 1-16. https://doi.org/10.1159/000551885

Vancouver

Abdulgayoom M, Afana MS, Saleh LH, Manthiri AA, Aweer NA, Bakheet M, et al. Venetoclax-Based Regimens in Chronic Myelomonocytic Leukemia: A Systematic Review and Meta-Analysis. Acta Haematologica. 2026:1-16. doi:10.1159/000551885

BibTeX
@article{Abdulgayoom2026,
  author = {Abdulgayoom, Mohammed and Afana, Mohammad S and Saleh, Leen Haj and Manthiri, Aadhila Abbas and Aweer, Noor A and Bakheet, Mohammad and Al-Mashdali, Abdulrahman F and Mohamed, Shehab F},
  title = {Venetoclax-Based Regimens in Chronic Myelomonocytic Leukemia: A Systematic Review and Meta-Analysis},
  journal = {Acta Haematologica},
  year = {2026},
  pages = {1--16},
  doi = {10.1159/000551885}
}
Kostenlos starten →